AstraZeneca's half 1 and Q2 2026 webinar for investors and analysts begins with global greetings and a Safe Harbor statement. The speaker emphasizes the use of the Safe Harbor revisions for forward-looking statements, highlighting the inherent risks and uncertainties. The Company commits to providing current information but will not update forward-looking statements, adhering to the U.S. Private Securities Litigation Reform Act of 1995.

AstraZeneca's Q2 2026 financial report highlights a 6% total revenue growth driven by innovative medicines, excluding generic impacts. Core EPS surged 11%, with significant advancements in pipeline programs, including approvals for new treatments in breast cancer and hypertension. The company reaffirms its commitment to expanding its portfolio and achieving its 2030 growth targets.

The company highlights robust growth in oncology, rare diseases, and respiratory immunology, despite challenges in China. Despite a setback in a CTF trial, positive results from six high-value programs and major market approvals support confidence in achieving the 80 billion revenue goal by 2030. Progress on the first 2030 growth is being actively pursued.

Revenue grew by 6%, with alliance revenue up 29%, driven by partner medicines. Core growth margin was 83%, with expected seasonal declines in the second half. RD expenses increased by 6%, reflecting investments in the pipeline, including oral GLP 1 molecule phase 3 programs. Core SG&A expenses rose, supporting launches and pre-launch investments. Core EPS grew, aligning with full-year guidance.

Discusses financial results, highlighting investments in growth, effects of milestones and exclusivity loss, debt increase due to dividends and deal payments, and guidance for revenue and EPS growth, emphasizing long-term strategic investments and financial priorities.

Oncology revenues increased by 15% to $14.1 billion, driven by double-digit growth in major regions. Notable growth was seen in the US and Europe, particularly for tigrisoma and calquence, which achieved $1 billion in quarterly revenue for the first time. Infinity and judo grew 25%, supported by new launches and increased demand. In HER2, growth of 31% was reported, with strong market leadership in major markets. The pipeline includes advancements in EGFR mutated lung cancer, with the licensing of zigfried and ongoing trials for DAA in combination therapies, aiming to maintain leadership and improve patient outcomes.

Recent Phase 3 trials demonstrated positive outcomes for pisi in bladder cancer and Sunny V in gastric cancer, showcasing improvements in survival rates and reinforcing the potential of combining immunotherapy with antibody-drug conjugates across multiple cancers.

Despite a 5% revenue decline due to lost activities and competition, the company experienced strong growth in respiratory products, including a 75% increase in asser sales in China. The portfolio also saw positive momentum in asthma treatments and intravenous segment share gains. Challenges included price pressures and generic competition, yet the company anticipates future success with new approvals and preparations for upcoming launches, showcasing resilience and strategic pipeline development.

Recent updates include the Phase 3 results of a gene silencer treatment for ATTR cardiomyopathy, promising Phase 2 outcomes for an oral GLP-1 receptor agonist in diabetes and obesity, advancements in weight management and dyslipidemia treatments, and progress in respiratory therapies, including COPD and asthma. Notably, aleco glyph on showed significant weight loss and glycemic control, while respiratory innovations like Tozer auma and tqc 3721 highlight potential breakthroughs in managing chronic diseases.

AstraZeneca reports a 11% growth in revenues to $4.9 billion, driven by increased patient demand and global expansion, with a focus on rare disease treatments. The company highlights the success of its medicines across various indications, including competitive markets like Mg and PNH, and the potential for future growth with the launch of cino de alpha. AstraZeneca's rare disease pipeline shows promise with phase II data presentations, phase III trial results for NGN ephorates, and advancements in treating conditions like bone health and cardiovascular disease. The company is advancing regulatory filings and exploring treatments in complement biology, aiming to bring innovative therapies to patients with severe complement-mediated diseases.

The dialogue highlights the company's strong momentum, with 25 key Phase 3 results planned over the next 18 months, expected to add value and conviction to their trajectory. It emphasizes investment in transformative technologies beyond 2030, showcasing progress in platforms identified in mid-2024. The focus is on innovation and growth, with a rich pipeline of catalysts and ambitious growth ambitions extending well into the future.

The dialogue highlights advancements in multiple phase 3 trials for various drug candidates, including E-coli prom, Sony V, and ADC pukis, with a focus on weight management and obesity. It also discusses the rapid progress in cell therapy, T-cell engineering, and in vivo cell therapy, which are integral to the company's broad pipeline aiming to address diverse disease areas. Key achievements include initiating 5 phase 3 trials for E-coli prom, anticipating phase 3 data for ADC pukis next year, and conducting first phase 3 trials for tovim and zra. The company's commitment to innovation and expanding its therapeutic platforms is emphasized as a foundation for future growth.

The company highlights its robust portfolio with blockbuster potential, exceeding $5 billion in peak revenue for three recent launches. Emphasizing diversification and risk-adjusted projections, it showcases successful developments like tozo akima and Sony V, contributing to a $25 billion revenue expectation. With strong growth in the first half, excluding cost CER, the firm remains confident in achieving $1 billion revenue by 2030, aiming to extend success into future decades through transformative technology platforms.

The dialogue covered expectations for an oral Pcsk9 medication's data release, pricing strategy, and competitive profile, alongside updates on Sunny V's potential in gastric cancer, discussing peak sales, geographic distribution, and life cycle planning.

Discussions revolve around the potential of combining IO and ADC therapies in gastric, pancreatic, and biliary cancers, emphasizing the role of endocrine sensitivity in treatment efficacy and patient selection. The dialogue highlights the importance of broadening treatment opportunities, considering early-stage interventions, and optimizing patient care through convenient formulations.

The dialogue focuses on the design of clinical trials aimed at enriching endocrine sensitivity populations, discussing the larger sample size in Serena 4 compared to previous trials. It highlights the overall tolerability profile observed in the seina 6 data, emphasizing low gastrointestinal side effects and discontinuation rates. The conversation also touches upon the differentiation of z.n.b.'s profile, particularly its performance in far loop versus near loop settings, and its competitive advantage in the market.

Zetrov, licensed from diesel for Exxon, shows strong efficacy against 20 mutations and non-classical mutations in lung cancer, achieving high response rates and durable outcomes. Its differentiated activity in the second-line setting has secured US labeling, with data from Asco presentations supporting first-line setting filings. Compared to competitors, Zetrov boasts ease of administration, favorable tolerability, and competitive potency, positioning it as a promising addition to lung cancer treatment.

The dialogue focuses on strategies to strengthen market presence and clinical development for therapies targeting EGFR mutated lung cancer, including expanding treatment options, leveraging combination therapies, and addressing competitive pressures to drive growth and meet ambitious targets.

The dialogue covers the outcomes of clinical trials, particularly focusing on the efficacy and differentiation of ADCs in treating cancers, and discusses potential market dynamics and therapeutic strategies for drugs, emphasizing confidence in the design and expected commercial performance across different regions.

The dialogue covers the add-on design of Pramet to Stabilis, emphasizing the depleting mechanism's benefits in amyloid treatment, and discusses Stan FIQ's improved tolerability and wider coverage potential over its competitor, highlighting patient retention and injection site reaction rates.

Discussed financial planning for 2026 and 2027, emphasizing the balance between investment in pipeline and launches versus margin expansion. Highlighted the probability of success in the Cambria 1 study for hormone receptor-positive breast cancer, focusing on endocrine-sensitive patient populations. Explored the potential of new drug combinations targeting high-risk patient groups, such as heart failure patients with low eGFR and those with chronic kidney disease and hypertension, underscoring the innovative potential and market need for these treatments.

The dialogue covers sales outlooks for drugs including pediatric and adult populations, excitement over prostate cancer treatment data, and financial guidance updates, emphasizing ongoing investments and pipeline potential.

The dialogue discusses advancements in prostate cancer treatments, focusing on the EPAR prostate O 1 trial, and addresses the launch strategy for aldosterone screening, emphasizing its potential impact on market opportunities and patient outcomes.

The dialogue highlights the significant unmet medical need in primary aldosteronism, emphasizing the approval of the first aldosterone synthase inhibitor. This development is expected to drive screening and treatment uptake, addressing a major cause of secondary hypertension and cardiovascular damage, with rapid study recruitment reflecting clinical enthusiasm for this breakthrough therapy.

A dialogue covers potential market competition for a 5 billion target drug, emphasizing the convincing nature of the data from pivotal trials. It discusses the unique mechanism of action of the drug, specific to the Nr 33, and the anti-inflammatory and mucous pathways. The conversation also touches on evolving source and pricing strategies for new drug approvals, comparing them to historical precedents, while maintaining a close watch on competitors' reactions to the data.

Despite challenges, the speaker remains bullish on China's economic potential, highlighting the country's innovation and the strategic partnership with global companies. The discussion acknowledges the growing threat of local companies expanding globally, emphasizing the need for collaboration and learning from their agile development processes. The role of Chinese teams in accelerating product development is recognized, indicating a dynamic competitive landscape in global markets.

The dialogue discusses strategies for competing in the C5 market and beyond, focusing on pioneering new indications and trials in areas like renal rare diseases and complement biology. It highlights ongoing efforts to develop new syndications and adapt to competition, emphasizing growth and innovation within the complement value market.

Discusses the sustainability of operating income, highlighting royalties, milestones, and proceeds from regional divestitures, emphasizing the consistency of these income sources into 2027.

Discusses whether the current phase three-i pipeline is sufficient to maintain stability through patent expirations, highlighting the importance of aggregate pipeline success rates. Confirms that new B is not necessary to meet 2030 goals, given historical performance exceeding industry averages. Addresses sales potential from 2026 readouts, noting positive unwinding of risks and adjustments for product partnerships. Touches on pricing strategies influenced by Mfn and the evolving approach to negotiations in wealthy nations, emphasizing longer discussions and alignment with global pricing benchmarks.

A company updates stakeholders on ongoing arbitration for Bay Fortis, reiterates commitment to 2030 goals, and states that additional bids are not necessary for achieving targets, though not ruled out. The dialogue closes with appreciation for participants' interest.